

14202
12-203

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

17302 U.S.PTO
10/734787

121203

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on

12/12/03

Date of deposit

Signature

EL 964822803 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2002/0036 US NP

INVENTORS: Thierry Canton, et al

TITLE: Application of intestinal biliary acid
uptake inhibitors for the prevention and treatment
of Alzheimer's disease

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>	Total Pages	<input type="text" value="31"/>
2. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (<i>if filed</i>) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	<input type="text" value="31"/>
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113)	Total Sheets	<input type="text" value="4"/>
4. Oath or Declaration	Total Pages	<input type="text" value="2"/>
a. <input checked="" type="checkbox"/> Newly unexecuted (original or copy)		
b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>		
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. Power of Attorney	Total Pages	<input type="text"/>
a. <input type="checkbox"/> Newly executed (original or copy)		
b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))		
6. <input type="checkbox"/> Microfiche Computer Program (<i>Appendix</i>)		

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- Computer Readable Copy
- Paper Copy (identical to computer copy)
- Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____.

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/455,354, filed March 17, 2003, and claims priority of French Application No. 0215722 filed December 12, 2002.
(The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement
(when there is an assignee)
9. Verified English Translation Document (*if applicable*)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)

Balaram Gupta

Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. FRAV2002/0036 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

Claims small entity status. See 37 C.F.R. 1.27.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 914.00)

www.english-test.net

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Filed Herewith
First Named Inventor	Thierry Canton, et al
Examiner Name	
Group / Art Unit	
Priority Document No.	EP-A-2002/0026 US-NP

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)				
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> Other	<input type="checkbox"/> None	3. ADDITIONAL FEES				
<input checked="" type="checkbox"/> Deposit Account					Large Entity		Small Entity		
Deposit Account Number	18-1982				Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
Deposit Account Name	Aventis Pharmaceuticals Inc.				1051	130	2051	65	Surcharge - late filing fee or oath
The Commissioner is authorized to: (check all that apply)					1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments					1053	130	1053	130	Non-English Specification
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application					1812	2,520	1812	2,520	For filing a request for reexamination
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account					1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
FEE CALCULATION					1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1. BASIC FILING FEE					1251	110	2251	55	Extension for reply within first month
Large Entity		Small Entity		Fee Description	1252	420	2252	205	Extension for reply within second month
Fee Code	Fee (\$)	Fee Code	Fee (\$)		1253	950	2253	465	Extension for reply within third month
1001	770	2001	375	Utility filing fee	1254	1,480	2254	725	Extension for reply within fourth month
1002	340	2002	165	Design filing Fee	1255	2,010	2255	985	Extension for reply within fifth month
1003	530	2003	260	Plant filing fee	1401	330	2401	160	Notice of Appeal
1004	770	2004	375	Reissue filing fee	1402	330	2402	160	Filing a brief in support of an appeal
1005	160	2005	80	Provisional filing fee	1403	290	2403	140	Request for oral hearing
SUBTOTAL (1)		(\$ 770.00)			1451	1,510	1451	1,510	Petition to institute a public use proceeding
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE					1452	110	2452	55	Petition to revive - unavoidable
					1453	1,330	2453	650	Petition to revive - unintentional
Total Claims	28	-20**=	8	x 18 = 144	1501	1,330	2501	650	Utility issue fee (or reissue)
Independent	3	- 3**=	0	x 86 = 0	1502	480	2502	235	Design issue fee
Claims					1503	640	2503	315	Plant issue fee
Multiple Dependent					1460	130	1460	130	Petitions to the Commissioner
Large Entity	Fee Description				1807	50	1807	50	Petitions related to provisional applications
Fee Code	Fee (\$)	Fee Code	Fee (\$)		1806	180	1806	180	Submission of Information Disclosure Stmt
1202	18	2202	9	Claims in excess of 20	8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1201	86	2201	42	Independent claims in excess of 3	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))
1203	290	2203	140	Multiple dependent claim, if not paid	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))
1204	86	2204	42	**Reissue independent claims over original patent	1801	770	2801	375	Request for Continued Examination (RCE)
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application
SUBTOTAL (2) (\$144.00)					Other fee (specify)				
**or number previously paid, if greater; For Reissues, see above					*Reduced by Basic Filing Fee Paid				
					SUBTOTAL (3) (\$)				

***or number previously paid, if greater; For Reissues, see above*

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Complete (*If applicable*)

Name (Print/Type)	Balaram Gupta, Reg. No. 40,009	Registration No. (Attorney/Agent)	40,009	Telephone	(908) 231-3364
Signature				Date	December 12, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template